BIOGEN INCBIIB
ASignal's systematic analysis rates BIIB as Neutral.
Reflects the latest available analysis · analyzed Sep 15, 2026
The case on BIIB
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong gross margin of 78.32% indicating pricing power
- Debt-to-equity ratio of 0.44x, below conservative threshold of 0.5
- Operating cash flow of $2.88B supports financial stability
- Forward P/E of 13.14x suggests better future valuation outlook
- Current price near lower Bollinger Band at $209.12, potential support
- Negative earnings growth of -84.80% year-over-year
- Trailing P/E of 38.68x above market average, raising valuation concerns
- PEG ratio of 2.24x indicates potential overvaluation relative to growth
- MACD histogram negative at -0.82, signaling weakening bullish momentum
- Quick ratio of 0.94x, below 1.0 may indicate short-term liquidity pressure
Peers
Clustered with BIIB by analysis-profile similarity.
See the full verdict on BIIB
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes BIIB
Most investors never get a second opinion, let alone several. ASignal runs BIIB past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.